ZNF683/HOBIT mRNA is preferentially expressed in NK cells compared to other human immune cells. During differentiation, ZNF683/HOBIT mRNA increases and accumulates in parallel to the generation of CD56+ NK cells. Interference with ZNF683/HOBIT expression resulted in a substantial reduction of CD56+ NK cells. However, the proportion of IFN-γ-producing cells appeared to be increased upon ZNF683/HOBIT knockdown.
Ovarian cancer represents the most common gynaecological malignancy and has the highest mortality of all female reproductive cancers. It has a rare predilection to develop brain metastases. Lukas Kenner has now contributed to a report on Next-Generation Sequencing (NGS)-based genomic profiling of brain metastases of primary ovarian cancer. The team from Vienna identified a high number of BRCA-mutations with a NGS study of samples from ovarian carcinoma, besides TP53, ATM and CHEK2 mutations.
The Ludwig Boltzmann Institute for Cancer Research (LBI-CR) consolidates scientific success with outstanding achievements. 2016 was again with respect to publications and the acquisition of external research funds at an unusually high level. Furthermore, the staff of the LBI-CR, together with partner institutions, were able to put significant emphasis on applied and clinically translational cancer research, which was also very popular in the media.
Type I interferons (IFNs) are known to mediate antitumor effects against several tumor types and have therefore been commonly used in clinical anticancer treatment. However, how IFN signaling exerts its beneficial effects is only partially understood. The clinically relevant activity of type I IFNs has been mainly attributed to their role in tumor immune surveillance. Different mechanisms have been postulated to explain how type I IFNs stimulate the immune system. On the one hand, they modulate innate immune cell subsets such as natural killer (NK) cells.
EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorectal tumors without RAS mutations. However, EGFR inhibitors are ineffective in these patients, and tumor level of EGFR does not associate with response to therapy.
The JAK2/STAT5 pathway is a novel potential target of therapy in canine mastocytoma, which is a frequently diagnosed cutaneous neoplasms in dogs. In non-resectable mastocytoma patients, novel targeted drugs are often applied. The transcription factor STAT5 has been implicated in the survival of human neoplastic mast cells. We have now reported the JAK2/STAT5 pathway as a novel target in canine mastocytoma.
New paper out on expression of DCLK1 in 127 patients being associated with poor survival. In particular, DCLK1 expression had a significant impact on survival of oropharyngeal carcinoma patients. Specifically, DCLK1+/HPV- patients had the worst prognosis after simultaneous assessment of DCLK1 and HPV status in comparison to the other three possible DCLK1/HPV constellations. Higher levels of DCLK1 mRNA were also associated with poor clinical outcome. Inhibition of DCLK1 in our HNSCC cell lines led to growth arrest and induction of apoptosis.
Lukas Kenner contributed to "Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer" recently published in Science Reports.
Seeking to exploit some of his recent discoveries Florian Grebien now launched a new project in cooperation with CeMM and the Structural Genomics Consortium, Toronto, Canada. With the financial support of the FFG "Industrianahe Dissertationen" PhD student Jessica Ebner will aim to target the epigenetic regulator WDR5 with an innovative approach.
Richard Moriggl and colleagues published their view on steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3.